6B0F

ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102

6B0F の概要

• エントリーDOI: 10.2210/pdb6b0f/pdb
• 分子名称: Estrogen receptor, LSZ102, GLYCEROL, ... (4 entities in total)
• 機能のキーワード: nuclear receptor, hormone receptor
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 59012.96

構造登録者

Kirby, C.A.,Baird, J. (登録日: 2017-09-14, 公開日: 2018-04-04, 最終更新日: 2024-04-03)

主引用文献

Tria, G.S.,Abrams, T.,Baird, J.,Burks, H.E.,Firestone, B.,Gaither, L.A.,Hamann, L.G.,He, G.,Kirby, C.A.,Kim, S.,Lombardo, F.,Macchi, K.J.,McDonnell, D.P.,Mishina, Y.,Norris, J.D.,Nunez, J.,Springer, C.,Sun, Y.,Thomsen, N.M.,Wang, C.,Wang, J.,Yu, B.,Tiong-Yip, C.L.,Peukert, S.
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
J. Med. Chem., 61:2837-2864, 2018

PubMed Abstract: In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ERα positive breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs). The steroid-based anti-estrogen fulvestrant (5), the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies. Its efficacy, however, may be limited due to its poor physicochemical properties. We describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs. This article culminates in the identification of LSZ102 (10), a compound in clinical development for the treatment of ERα positive breast cancer.

PubMed: 29562737
DOI: 10.1021/acs.jmedchem.7b01682

実験手法

X-RAY DIFFRACTION (2.86 Å)